Two Sigma Investments LP Boosts Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Two Sigma Investments LP boosted its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 33.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 266,482 shares of the company's stock after purchasing an additional 67,174 shares during the period. Two Sigma Investments LP owned about 0.59% of Apogee Therapeutics worth $12,072,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of APGE. Optimize Financial Inc bought a new stake in shares of Apogee Therapeutics in the fourth quarter valued at $203,000. Aigen Investment Management LP bought a new stake in shares of Apogee Therapeutics in the fourth quarter valued at $216,000. BNP Paribas Financial Markets bought a new stake in shares of Apogee Therapeutics in the fourth quarter valued at $219,000. Commonwealth Equity Services LLC bought a new stake in shares of Apogee Therapeutics in the fourth quarter valued at $222,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Apogee Therapeutics in the fourth quarter valued at $226,000. Hedge funds and other institutional investors own 79.04% of the company's stock.

Insiders Place Their Bets

In other Apogee Therapeutics news, insider Carl Dambkowski sold 3,860 shares of the company's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $36.22, for a total value of $139,809.20. Following the transaction, the insider now directly owns 247,173 shares in the company, valued at $8,952,606.06. This represents a 1.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael Thomas Henderson sold 10,000 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total value of $301,500.00. Following the completion of the transaction, the chief executive officer now owns 1,292,987 shares in the company, valued at $38,983,558.05. This represents a 0.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,175 shares of company stock worth $587,191 in the last ninety days. 42.77% of the stock is currently owned by insiders.

Apogee Therapeutics Stock Up 3.1%

APGE traded up $1.12 during trading on Thursday, reaching $37.52. 81,663 shares of the company were exchanged, compared to its average volume of 525,165. The company's 50-day moving average is $36.59 and its two-hundred day moving average is $40.22. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -15.49 and a beta of 1.70. Apogee Therapeutics, Inc. has a 12-month low of $26.20 and a 12-month high of $63.50.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.19) by $0.24. Equities analysts forecast that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Wall Street Analyst Weigh In

APGE has been the topic of several research reports. Guggenheim restated a "buy" rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Citigroup initiated coverage on Apogee Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $95.00 target price on the stock. Finally, Wedbush restated an "outperform" rating and issued a $90.00 target price on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $94.60.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.